Bronchiolitis in Infants Placebo Versus Epinephrine and Dexamethasone Study

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (313 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-05-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: placebogreaterrandomizedmildadmission
  Phrases that lowered it: trialpatientsdexamethasoneparticipate inasthma
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 12.9% (raises risk) · Sponsor's track record
• Collaborators: 8 (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Minimum age: 0.16 (lowers risk) · Who can join
• Drug's FAERS reports with a death: 17.0% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 184270 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Disease area, respiratory: Yes (raises risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 36792 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma NCT01065272 · started 2010 · scored riskier than 21% of active trials completed
• Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies. NCT02586961 · started 2015 · scored riskier than 34% of active trials terminated
• Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids. NCT01272635 · started 2011 · scored riskier than 33% of active trials completed
• CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST) NCT00675584 · started 2008 · scored riskier than 22% of active trials completed
• Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age NCT03959384 · started 2019 · scored riskier than 47% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.